Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, is dedicated to developing therapies for the treatment of Alzheimer's disease and other neurodegenerative diseases. The company is headquartered in Charlottesville, Virginia.
| Revenue (TTM) | 329,000 |
| Gross Profit (TTM) | $-104.93M |
| EBITDA | $-114.56M |
| Operating Margin | 0.00% |
| Return on Equity | -93.20% |
| Return on Assets | -42.40% |
| Revenue/Share (TTM) | $0.03 |
| Book Value | $1.21 |
| Price-to-Book | 1.82 |
| Price-to-Sales (TTM) | 538.78 |
| EV/Revenue | 24.48 |
| EV/EBITDA | -0.60 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $72.23M |
| Float | $36.96M |
| % Insiders | 6.80% |
| % Institutions | 64.64% |
Volatility is currently contracting
Acumen Pharmaceuticals (ABOS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Here is how Acumen Pharmaceuticals, Inc. (ABOS) and Amarin (AMRN) have performed compared to their sector so far this year.
NEWTON, Mass., July 15, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (Acumen), a clinical-stage biopharmaceutical company developing novel therapeutics that target soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD), today announced new findings presented at the Alzheimer's Association International Conference (AAIC®) 2026 in London. Following collaboration with JCR Pharmaceuticals Co., Ltd. (JCR) on EBD candidate development, studies demonstrated improved brain penetration of anti-AβO antibodies through transferrin receptor-mediated delivery across both mouse and non-human primate models. Additionally, research from early symptomatic AD patients highlighted the lived experience among ALTITUDE-AD trial participants and their study partners.
NEWTON, Mass., July 07, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (Acumen), a clinical-stage biopharmaceutical company developing novel therapeutics that target soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD), will present three key studies at the upcoming Alzheimer's Association International Conference (AAIC®) 2026 in London. Shared in one oral and two poster presentations, the data highlight Acumen's progress with JCR Pharmaceuticals (JCR), in developing next generation therapeutics through Enhanced Brain Delivery (EBD) technology and expanding the field's understanding of early symptomatic AD through the patient lens. The conference will be held July 12-15, 2026, both in-person and online.
ACU301 and ACU401 were nominated in the EBD program as part of the exercise of Acumen's option under its license agreement with JCR Pharmaceuticals EBD technology represents the only anti-amyloid oligomer program combining a validated blood-brain barrier-penetrating technology with a therapeutic antibody tested in the clinic Acumen's EBD candidates are designed to achieve higher brain penetration with potential for improved safety compared to native antibodies and delivered in a stable, low volume subcutaneous administration format Investigational New Drug (IND)-enabling activities are ongoing to support IND submission in mid-2027 NEWTON, Mass., June 16, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (Acumen or the Company), a clinical-stage biopharmaceutical company developing novel therapeutics that target soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD), today announced the nomination of two development candidates in its Enhanced Brain Delivery (EBD) program as treatments for AD.
Acumen Pharmaceuticals is a clinical-stage Alzheimer's biotech built around sabirnetug. I believe 2026 will be mostly about its upcoming Phase 2 readout. The main appeal still lies with sabirnetug, which could offer meaningful upside if Phase 2 data supports a viable path into Phase 3. As such, ALTITUDE-AD is the main swing factor, especially if iADRS slowing lands near management's target.
Acumen Pharmaceuticals, Inc. (ABOS) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Acumen Pharmaceuticals, Inc. (ABOS) Q1 2026 Earnings Call Transcript
Acumen Pharmaceuticals NASDAQ: ABOS said its Phase 2 ALTITUDE-AD trial of sabirnetug remains on track, with top-line results expected late in 2026, as the company continues to advance its broader Alzheimer's disease pipeline.
NEWTON, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD), today reported financial results for the first quarter of 2026 and provided a business update.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on ABOS and any ticker you trade — then tracks every position and per-strategy win rate.
